Document Detail

Anticoagulation in ischemic stroke: opportunities in arterial disease.
MedLine Citation:
PMID:  16327259     Owner:  NLM     Status:  MEDLINE    
In the acute phase of ischemic stroke, there is no evidence that anticoagulants provide any benefit in terms of death or dependency. A small reduction in the incidence of recurrent stroke is offset by an equally small increase in intracranial hemorrhage (ICH). In the secondary prevention of stroke, in patients with transient ischemic attacks (TIAs) and moderately disabling ischemic stroke, the relative risk reduction of major vascular events by aspirin is rather modest: 13% (or 19% in a systematic review of arterial disease in general). Anticoagulants might well offer stronger protection, since they provide a 35-50% risk reduction after myocardial infarction or in patients with TIAs or nondisabling ischemic stroke in the presence of atrial fibrillation. Meanwhile, it has become clear that anticoagulation with high intensity (INR 3.0-4.5) is associated with a high risk of ICH in patients with cerebral ischemia who are in sinus rhythm, while INR values around 1.9 do not offer protection against major vascular events. An international clinical trial of anticoagulation with INR values between 2.0 and 3.0 (ESPRIT) is still in progress. In cerebral venous sinus thrombosis, anticoagulant treatment is associated with a nonsignificant reduction of the risk of death or dependence, but the treatment has nevertheless become widely adopted because it seems safe: no increase in the proportion of patients with hemorrhagic transformation of infarction has so far been demonstrated.
J van Gijn; A Algra
Related Documents :
25411049 - Relationship between the hypersensitive c-reactive protein (hs-crp) level and the progn...
3665289 - Risk of early anticoagulation in patients with small deep infarcts possibly caused by c...
18460709 - Percutaneous coronary intervention in a patient with acute st-elevation myocardial infa...
18594479 - Will warfarin soon be passé? new approaches to stroke prevention in atrial fibrillation.
10082099 - Long-term follow-up of vena tech-lgm filter: predictors and frequency of caval occlusion.
11693739 - Role of transesophageal echocardiography-guided cardioversion of patients with atrial f...
16752359 - Percutaneous transhepatic thrombolysis in the treatment of acute portal venous thrombosis.
11173319 - Massive congenital coronary arteriovenous malformation presenting with exertional dyspn...
2050429 - Evaluation of receiver operator characteristics--optimum time of day for the assessment...
Publication Detail:
Type:  Journal Article; Review     Date:  2005-12-02
Journal Detail:
Title:  Cerebrovascular diseases (Basel, Switzerland)     Volume:  20 Suppl 2     ISSN:  1015-9770     ISO Abbreviation:  Cerebrovasc. Dis.     Publication Date:  2005  
Date Detail:
Created Date:  2005-12-05     Completed Date:  2006-01-25     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9100851     Medline TA:  Cerebrovasc Dis     Country:  Switzerland    
Other Details:
Languages:  eng     Pagination:  101-8     Citation Subset:  IM    
Copyright Information:
2005 S. Karger AG, Basel
Department of Neurology, University Medical Centre, Utrecht, The Netherlands.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Anticoagulants / therapeutic use*
Brain Ischemia / drug therapy
Clinical Trials as Topic
Intracranial Arterial Diseases / etiology*,  prevention & control*
Intracranial Thrombosis / drug therapy
Stroke / drug therapy*,  prevention & control
Reg. No./Substance:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Vascular dementia prevention: a risk factor analysis.
Next Document:  Antiplatelets in stroke prevention: the MATCH trial. Some answers, many questions and countless pers...